ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $216M

      Shares

      2.93M

      % of Portfolio

      0.16%

      Average Buy Price

      $70.7

      Avg closing price
      Price range

      49 PRIMECAP Management CVS Health Trades

      PRIMECAP Management's position in CVS Health is currently worth $216M. That's 0.16% of their equity portfolio (104th largest holding). The first CVS Health trade was made in Q1 2013. Since then PRIMECAP Management bought shares seventeen more times and sold shares on 31 occasions. The stake costed the investor $207M, netting the investor a gain of 4.2% so far.

      Avg closing price
      Price range
      Increased shares by 0.4% (+12.9k shares) Q2 2025
      Avg closing price $65.57
      Price range $60.04 - $70.18
      Sold 2.7% shares (-81k shares) Q1 2025
      Avg closing price $59.61
      Price range $44.22 - $68.64
      Sold 6.7% shares (-214k shares) Q4 2024
      Avg closing price $55.81
      Price range $43.93 - $67.46
      Sold 4.5% shares (-151k shares) Q3 2024
      Avg closing price $58.30
      Price range $55.81 - $63.18
      Sold 1.0% shares (-33.1k shares) Q2 2024
      Avg closing price $62.55
      Price range $53.63 - $79.56
      Sold 1.4% shares (-48.4k shares) Q1 2024
      Avg closing price $76.39
      Price range $71.99 - $81.42
      Increased shares by 0.5% (+16.7k shares) Q4 2023
      Avg closing price $71.17
      Price range $66.29 - $79.00
      Sold 1.9% shares (-66k shares) Q3 2023
      Avg closing price $70.86
      Price range $65.17 - $76.41
      Sold 6.2% shares (-229k shares) Q2 2023
      Avg closing price $71.15
      Price range $66.65 - $77.75
      Sold 3.3% shares (-126k shares) Q1 2023
      Avg closing price $83.86
      Price range $72.37 - $92.91
      Sold 4.5% shares (-183k shares) Q4 2022
      Avg closing price $96.49
      Price range $87.84 - $103.79
      Sold 1.1% shares (-43.2k shares) Q3 2022
      Avg closing price $98.99
      Price range $92.53 - $106.43
      Sold 1.4% shares (-58.1k shares) Q2 2022
      Avg closing price $97.60
      Price range $88.66 - $106.64
      Sold 3.1% shares (-130k shares) Q1 2022
      Avg closing price $105.05
      Price range $100.77 - $110.83
      Sold 1.6% shares (-71k shares) Q4 2021
      Avg closing price $92.41
      Price range $83.15 - $103.70
      Sold 1.1% shares (-48.7k shares) Q3 2021
      Avg closing price $83.76
      Price range $80.05 - $87.47
      Sold 2.8% shares (-124k shares) Q2 2021
      Avg closing price $81.89
      Price range $73.79 - $89.81
      Sold 3.1% shares (-143k shares) Q1 2021
      Avg closing price $72.84
      Price range $68.13 - $76.30
      Sold 5.6% shares (-275k shares) Q4 2020
      Avg closing price $65.04
      Price range $55.93 - $74.50
      Sold 4.1% shares (-211k shares) Q3 2020
      Avg closing price $62.22
      Price range $56.71 - $65.71

      News about CVS Health Corp and PRIMECAP Management

      New CVS Health CEO Shakes Up Management, Commits To Integrated Model

      New CVS Health CEO Shakes Up Management, Commits To Integrated Model

      New CVS Health chief executive officer David Joyner promoted an internal executive, Prem Shah, as group president of the company and hired former UnitedHealt...

      forbes.com forbes.com, 10 months ago
      Glenview Capital: We Don't Want CVS Health Broken Up

      Glenview Capital: We Don't Want CVS Health Broken Up

      Glenview Capital Management, a hudge fund that has been subject of certain media reports that it was pushing CVS Health management to break up the healthcare...

      forbes.com forbes.com, 11 months ago
      CVS Health: Glenview's Activism Ramps Up Pressure On Management

      CVS Health: Glenview's Activism Ramps Up Pressure On Management

      CVS has faced consecutive guidance downgrades and a significant share price drop due to underperformance in its Medicare Advantage segment and rising costs. ...

      seekingalpha.com seekingalpha.com, 11 months ago
      Hedge fund Sachem Head built CVS stake during second quarter

      Hedge fund Sachem Head built CVS stake during second quarter

      Investment firm Sachem Head Capital Management built a new stake in CVS Health Corp during the second quarter when the healthcare company's stock price dropp...

      reuters.com reuters.com, about 1 year ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×